(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 April 2009 (23.04.2009)

PCT

(10) International Publication Number
WO 2009/052249 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 47/48* (2006.01)

(21) International Application Number:
PCT/US2008/080102

(22) International Filing Date: 16 October 2008 (16.10.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/981,411 19 October 2007 (19.10.2007) US

(71) Applicant *(for all designated States except US)*: **GENENTECH, INC.** [US/US]; 1 Dna Way, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MAO, Weiguang** [US/US]; 1613 De Anza Blvd., San Mateo, CA 94403 (US). **JUNUTULA, Jagath, Reddy** [IN/US]; 34391 Tupelo Street, Fremont, CA 94555 (US). **POLAKIS, Paul** [US/US]; 260 Corte Madera Avenue, Mill Valley, CA 94941 (US).

(74) Agents: **GINGER, R., Dreger** et al.; Goodwin Procter LLP, 135 Commonwealth Drive, Menlo Park, CA 94025 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

WO 2009/052249 A1

(54) Title: CYSTEINE ENGINEERED ANTI-TENB2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

(57) Abstract: Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TKNB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)$_p$ I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.